Medical Marijuana Inc (PK) (MJNA) News

0.01 to .40 a while back

Terrible what happened here

Lol 0.0001

Wonder r s ???????

Wished I had bought at 0.01

0.01 to .40 a while back

Soon 0.0001

0.0001

In case u haven't noticed "O" ZERO care about ones dumb thoughts/opinion of worthless projections

I wish you didn't yell all the time , I find that I don't read your posts...sorry

***** Hilarious ! now I am hearing MJNA turd is worth 5 bucks ? Why ? fins state otherwise -- whoopsie !








ENOUGH SAID

WELL !! GREAT NEWS DELERIOUS !! THANKS !! THERE ARE 5 OF US POSTING THAT KNOW WHAT IN THE HELL IS GOING ON !! SAVING GRACE IS AT THE TOP OF MY LIST OF SMART PEOPLE !! THANK YOU FOR INCOURIGING ME WHEN I WANT TO GIVE UP !! THE DAM ASSSSES WHO DRAG THIS STOCK DOWN WILL GET THEIR DAY OF HELL WHEN THIS SHOOTS UP AND THEY ARE SHORT !! SHORT SQUEZZ - OH YA !! THIS IS A GREAT STOCK THAT IS WAITING FOR THE BIG ASS TRADERS TO FIND IT !! HELL -- THEY WANT EXPENSIVE DOLLARS STOCK !! THIS SHOULD BE A 5 DOLLAR STOCK !!!! MJNA IS AS GOOD AS GREEN THUMB GTBIF AT 12 $ !! ALL THE NEWS HAVE SAID WHAT A GREAT STOCK THIS IS !! I GUESS MJNA IS NOT SELLING WEED SO IT IS BLACK BALLED ON THE PRICE !! WELL US LONGS DAY WILL COME THE END OF JULY !! RECLASSIFICATION TO A 3 !!!! YES !! LONG OVER DUE !! THANK GOD FINALLY !! GO LONGS !! LONG AND STRONG !! THE FUTURE RICH BIG D !!!! MJNA $$$$

Fence riders never have any validity, thus NO "Trust" in one trying to play both sides of a fence, just hollow rhetoric.

Short selling, really

Strange company

Anyone buy at 0.01

Getting interesting

A while saw at 0.01 and went to .40

0.0001 terrible what happened here

Todays MJNA news release met w/ a resounding thud, thus RS imminent

Medical Marijuana, Inc. Portfolio Investment Company Neuropathix Announces Grant Award For Parkinson's Research
SAN DIEGO, CA -(NewMediaWire) - June 26, 2024 - Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), announced today that Kannalife Sciences, Inc. (Kannalife"), a wholly-owned subsidiary of the Company's portfolio investment company Neuropathix, Inc., a pioneering biotech company specializing in the development of small molecule synthetic cannabinoid therapeutics targeting inflammation, was awarded grant funding of $1.49 million for its Parkinson’s research using its Cannabinoid Therapeutic KLS-13019. The Company owns approximately 22% of Neuropathix.

Read the full Press Release here: https://www.globenewswire.com/news-release/2024/06/25/2903784/0/en/Kannalife-Secures-Funding-of-1-49-Million-from-The-Michael-J-Fox-Foundation-for-Parkinson-s-Research.html

Medical Marijuana, Inc. Chairman and CEO, Tim Scott, commented on the news; "We are one of Neuropathix’s largest shareholders and the securing of this grant to its wholly-owned subsidiary Kannalife is a very welcome development. We believe that Kannalife's proprietary cannabinoid therapeutic KLS-13019 has the potential to show efficacy in preclinical studies and subsequently move into more meaningful clinical trials to be tested as an effective treatment for Parkinson's Disease. If such potential for KLS-13019 were to be realized, we believe it would have a significant impact on the value of the Company’s investment portfolio given its large ownership stake in Kannalife's parent company, Neuropathix. Accordingly, we're very excited that the grant funding will provide Kannalife with the ability to conduct Parkinson's research using KLS-13019."

Going to trade sideways at least until August and probably into September-October. IMO

Wonder if a buy

Interesting company

0.0001

Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research
June 25, 2024 08:30 ET
| Source: Kannalife Sciences, Inc.






Funding of $1.49 million USD to support the development of KLS-13019 targeting neuroinflammation and mitochondrial dysfunction
Kannalife has developed a new class of orally bioavailable drugs to address neurodegenerative and inflammatory diseases by targeting mNCX-1, GPR55 and the NLRP3 inflammasome
DOYLESTOWN, PA, June 25, 2024 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc., a pioneering biotech company dedicated to developing small molecule therapeutics targeting inflammation, is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This grant will support preclinical research of Kannalife’s lead therapeutic KLS-13019 by investigating its effects on neuroinflammation and mitochondrial dysfunction, which are implicated in Parkinson’s disease (PD).

Parkinson’s disease is the fastest growing neurodegenerative movement disorder affecting up to 2% of those aged 60 years or older.

Douglas Brenneman, PhD, Chief Pharmacologist at Kannalife Sciences and Principal Investigator of the study, expressed gratitude for the Foundation's support, stating, "We are honored to receive this grant support from The Michael J. Fox Foundation, a leading organization dedicated to accelerating the development of improved therapies for Parkinson's disease. We are confident that we can make meaningful progress toward this goal and, ultimately, improve the lives of patients living with Parkinson's."

Kannalife Sciences, located at the Pennsylvania Biotechnology Center (PABC) in Doylestown, PA, is leveraging its globally patented technology into neuroinflammatory disorders targeting the novel G protein-coupled receptor (GPCR), GPR55 and the NLRP3 inflammasome. Advanced preclinical research and IND enabling studies to date have validated KLS-13019’s effects on biological targets in the mitochondria including mNCX-1, with the aim of addressing unmet needs in inflammatory diseases. KLS-13019’s promising preclinical results in models of neuroinflammation and oxidative stress, portend to be key factors of neurodegeneration in Parkinson's disease.

Jessica Tome Garcia, PhD, associate director of research programs at MJFF, stated, "We look forward to seeing the results of Kannalife Sciences’ innovative work on KLS-13019. This funding highlights the Foundation’s commitment to advancing Parkinson’s therapeutic research by addressing neuroinflammation and mitochondrial dysfunction, two key factors in the disease."

Dr. Brenneman further stated, “This grant represents a significant milestone in our research efforts. Special thanks to the whole team at Kannalife, especially Dean Petkanas for his persistence and dedication in mobilizing KLS-13019 into a potential therapeutic for the treatment of Parkinson’s Disease. I also want to thank our research partners Prof. Dr. Med. Chi Wang Ip of Universitätsklinikum Würzburg, Tom H. Johnston, PhD of Atuka, Inc. and James P. Koprich, MA, PhD, for taking the time and effort to put an outstanding study protocol together for our research program in PD.”

Through research efforts with MJFF and other partners, the company aims to accelerate the development of KLS-13019 and pave the way for novel therapeutic interventions in Parkinson’s disease and beyond.

KLS-13019 is currently undergoing small pre-clinical model efficacy, chemical scale-up, and toxicology studies supported by an STTR Phase 2 study grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) under the HEAL Initiative. Successful completion of these IND enabling studies will allow initiation of human clinical studies for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). This financial support underscores the broad scientific validation of this promising therapeutic agent.

About the Pennsylvania Biotechnology Center (PABC):
The PABC is a nonprofit life sciences incubator-accelerator providing state-of-the-art laboratory and office space to early-stage biotech companies, the Hepatitis B Foundation, and the Blumberg Institute. Managed by the Institute and overseen by a Foundation-appointed board, PABC supports nearly 80 member companies fostering success through biotech advancements and collaborations. Located near Doylestown in the Philadelphia-New Jersey pharma belt, the PABC website offers further information, visit www.pabiotechbc.org.

About Kannalife Sciences
Kannalife Sciences, Inc. is a pioneering biotech company specializing in the development of small molecule synthetic cannabinoid therapeutics targeting inflammation. Headquartered at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA, Kannalife Sciences is a wholly owned subsidiary of Neuropathix, Inc. For more information about Kannalife, visit www.kannalife.com and the Company’s Twitter page at @kannalife.

Contacts:

Media Relations
Thoma Kikis
Chief Communications Officer
P: +1-917-652-2479
E: thoma@kannalife.com
www.kannalife.com

***** LMAO ! Been hearing this nonsense for years ! yet MJNA turd continues t trade sub pennies - whoops

ENOUGH SAID

0.0001 and then what, reverse split......This is the more than likely scenario that will occur

SAVING GRACE !! THAT WAS A GOOD POST !! HOW HIGH DO YOU THINK MJNA $$ WILL GO WHEN WE FINALLY GET MARY JANE RE CLASSIFIED AT END OF JULY ?? IN THE LAST 5 YEARS 20 CENTS HAS BEEN THE MAGIC NO !! YES I HOPE FOR 1.30 $ !! WE MIGHT AS WELL HOPE FOR A HOME RUN !! WELL-- SOME PEOPLE SOLD TODAY AND LOST THEIR ASSES !! 20 MILLION SHARES ! THIS STOCK SHOULD BE AT ONE DOLLAR TO TWO DOLLARS !! WOW !! I WOULD BE HAPPY !! I HOPE THE SHORTS HERE LOSE THEIR ASSES !!!! WHEN I SELL OUT FOR MILLIONS I WILL LEAVE THIS CROOKED MARKET !! GOOD LUCK TO LONGS !! TRUST UNITS I CAN NOT FIGURE OUT YOUR POSTS ?? THE BIG D $$$$ !! GOD IS WITH US AND WE WILL WIN THIS FIGHT SHORTLY !!!!

New legislation to bankrupt short selling banks and hedge funds across the market shortly.

Green is Good!

Huzzah! Green is Good? Asking 4 a Friend✅

Neat stuff

Mini run afterwards

Saw 0.01 to .40 a while back

0.0001 and then what, reverse split

Interesting company

NOTHING TO SERE HERE!!!......BAIL OUT SP O.OOO2 YIKES!!!

WELL !! THIS GREAT STOCK MJNA IS BEING SLOWLY HAMMERED DOWN !! THANKS SAVING GRACE FOR GREAT POSTS !! THE COMPANY COULD BUY BACK A HELL OF A LOT OF SHARES FOR A LITTLE MONEY !! I HAVE NOT LOST ANY MONEY !! BECAUSE I DO NOT HAVE TO SELL AT REDICULOUS .0017 PRICES !!!! I WILL BUY 10000 $ MORE SOON = TO COME OFF THE BOTTOM AND MAKE MORE MONEY WHEN THIS GREAT- CHEAP STOCK RUNS WAY UP !! THIS IS A 2 DOLLAR STOCK SO I CAN SELL !! WOW !! WHAT A FORTUNE I WILL HAVE !! THAN I WILL BE A BIG PLAYER !! OH YA !! I CAN PLAY THE GAMES THE BIG BOYS DO AND SCREW US SMALL INVESTORS EVERY DAY !! OUR DAY WILL COME SOON !! END OF JULY !! LONGS HOLD ON !! RAT FINK HAS LEFT THE HOUSE !! ME AND SAVING GRACE ARE PUMPING THIS GREAT STOCK TO WHERE IT SHOULD BE TRADING !! GO MJNA TO THE MOON $$$$ !! THE BIG D $$$$ !!

***** NOPE ! Theres no MJNA turd share buy back coming -- whoops ! ( perhaps a link from the coming stating such could be posted )



ENOUGH SAID

Hallucination can be very costly

Yup, share buy back coming.

Getting interesting, r s anyone thinks, or fka ??????? Speculating

Terrible what happened here

***** LMAO ! A share buy back for a dead stock trading at .0017 - Whoops ! - now I've heard everything - SMH



ENOUGH SAID

Maryland governor pardons 175,000 marijuana convictions

https://www.axios.com/2024/06/17/maryland-pardon-marijuana-convictions-moore

Share buy back is the word, I'm hearing.

A while back 0.01 to 40 and 700,000,000 shares outstanding

Maybe r s

Probably 0.0001 and then what

Right on, when mirrored aliases start showing up, It's going to be a huge comeback for Medical Marijuana Inc.

It's a tell "tail" sign.